{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:22:07Z","timestamp":1764332527036,"version":"3.46.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The National Science Foundation of China","award":["82302936"],"award-info":[{"award-number":["82302936"]}]},{"name":"the National Science Foundation of China","award":["82372708"],"award-info":[{"award-number":["82372708"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26858-5","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:25:54Z","timestamp":1764325554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PIK75 effectively reverses PI3K\u2012AKT activation caused by palbociclib resistance and synergistically inhibits the progression of esophageal squamous cell carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Yaning","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"5","key":"26858_CR1","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.3892\/ijo.2015.2903","volume":"46","author":"S Fujihara","year":"2015","unstructured":"Fujihara, S. et al. Antidiabetic drug Metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. Int. J. Oncol. 46 (5), 2172\u20132180 (2015).","journal-title":"Int. J. Oncol."},{"issue":"1","key":"26858_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-022-03311-z","volume":"20","author":"T Yang","year":"2022","unstructured":"Yang, T. et al. Untargeted metabolomics analysis of esophageal squamous cell cancer progression. J. Translational Med. 20 (1), 127 (2022).","journal-title":"J. Translational Med."},{"key":"26858_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jare.2022.10.007","volume":"50","author":"B Zhou","year":"2023","unstructured":"Zhou, B. et al. Global burden and Temporal trends in incidence and mortality of oesophageal cancer. J. Adv. Res. 50, 135\u2013144 (2023).","journal-title":"J. Adv. Res."},{"issue":"1","key":"26858_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-023-01839-2","volume":"22","author":"L An","year":"2023","unstructured":"An, L., Li, M. & Jia, Q. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma. Mol. Cancer. 22 (1), 140 (2023).","journal-title":"Mol. Cancer"},{"issue":"1","key":"26858_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.athoracsur.2016.06.070","volume":"103","author":"SA Saddoughi","year":"2017","unstructured":"Saddoughi, S. A. et al. Survival after surgical resection of stage IV esophageal cancer. Ann. Thorac. Surg. 103 (1), 261\u2013266 (2017).","journal-title":"Ann. Thorac. Surg."},{"key":"26858_CR6","doi-asserted-by":"publisher","first-page":"1330785","DOI":"10.3389\/fimmu.2024.1330785","volume":"15","author":"DD Wei","year":"2024","unstructured":"Wei, D. D. et al. Perioperative immunotherapy for esophageal squamous cell carcinoma. Front. Immunol. 15, 1330785 (2024).","journal-title":"Front. Immunol."},{"issue":"11","key":"26858_CR7","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1016\/j.apsb.2021.03.008","volume":"11","author":"S He","year":"2021","unstructured":"He, S., Xu, J., Liu, X. & Zhen, Y. Advances and challenges in the treatment of esophageal cancer. Acta Pharm. Sinica B. 11 (11), 3379\u20133392 (2021).","journal-title":"Acta Pharm. Sinica B"},{"issue":"1","key":"26858_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-020-00323-3","volume":"5","author":"YM Yang","year":"2020","unstructured":"Yang, Y. M., Hong, P., Xu, W. W., He, Q. Y. & Li, B. Advances in targeted therapy for esophageal cancer. Signal. Transduct. Target. Therapy. 5 (1), 229 (2020).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"2","key":"26858_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2133.1996.tb07612.x","volume":"134","author":"YL Wang","year":"1996","unstructured":"Wang, Y. L., Uhara, H., Yamazaki, Y., Nikaido, T. & Saida, T. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br. J. Dermatol. 134 (2), 269\u2013275 (1996).","journal-title":"Br. J. Dermatol."},{"key":"26858_CR10","doi-asserted-by":"crossref","unstructured":"Ding, L. et al. The roles of Cyclin-Dependent kinases in Cell-Cycle progression and therapeutic strategies in human breast cancer. International J. Mol. Sciences 21(6), (2020).","DOI":"10.3390\/ijms21061960"},{"issue":"4","key":"26858_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6 (4), 353\u2013367 (2016).","journal-title":"Cancer Discov."},{"issue":"3","key":"26858_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal, C. L. et al. Inhibiting CDK4\/6 in breast cancer with Palbociclib, Ribociclib, and abemaciclib: similarities and differences. Drugs 81 (3), 317\u2013331 (2021).","journal-title":"Drugs"},{"key":"26858_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","volume":"45","author":"E Hamilton","year":"2016","unstructured":"Hamilton, E. & Infante, J. R. Targeting CDK4\/6 in patients with cancer. Cancer Treat. Rev. 45, 129\u2013138 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"26858_CR14","doi-asserted-by":"publisher","first-page":"852383","DOI":"10.3389\/fonc.2022.852383","volume":"12","author":"Q Luo","year":"2022","unstructured":"Luo, Q. et al. PI3K\/Akt\/mTOR signaling pathway: role in esophageal squamous cell Carcinoma, regulatory mechanisms and opportunities for targeted therapy. Front. Oncol. 12, 852383 (2022).","journal-title":"Front. Oncol."},{"issue":"1","key":"26858_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A. et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer. 22 (1), 138 (2023).","journal-title":"Mol. Cancer"},{"issue":"1","key":"26858_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal. Transduct. Target. Therapy. 6 (1), 425 (2021).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"4","key":"26858_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1042\/BST20190845","volume":"48","author":"M Fox","year":"2020","unstructured":"Fox, M., Mott, H. R. & Owen, D. Class IA PI3K regulatory subunits: p110-independent roles and structures. Biochem. Soc. Trans. 48 (4), 1397\u20131417 (2020).","journal-title":"Biochem. Soc. Trans."},{"key":"26858_CR18","doi-asserted-by":"publisher","first-page":"817916","DOI":"10.3389\/fonc.2022.817916","volume":"12","author":"R Huang","year":"2022","unstructured":"Huang, R. et al. A review: PI3K\/AKT\/mTOR signaling pathway and its regulated eukaryotic translation initiation factors May be a potential therapeutic target in esophageal squamous cell carcinoma. Front. Oncol. 12, 817916 (2022).","journal-title":"Front. Oncol."},{"issue":"9","key":"26858_CR19","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1158\/1078-0432.CCR-12-3559","volume":"19","author":"H Shigaki","year":"2013","unstructured":"Shigaki, H. et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin. Cancer Research: Official J. Am. Association Cancer Res. 19 (9), 2451\u20132459 (2013).","journal-title":"Clin. Cancer Research: Official J. Am. Association Cancer Res."},{"issue":"3","key":"26858_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3892\/ijo_00000202","volume":"34","author":"I Akagi","year":"2009","unstructured":"Akagi, I. et al. Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. Int. J. Oncol. 34 (3), 767\u2013775 (2009).","journal-title":"Int. J. Oncol."},{"key":"26858_CR21","doi-asserted-by":"publisher","first-page":"15290","DOI":"10.1038\/ncomms15290","volume":"8","author":"J Chang","year":"2017","unstructured":"Chang, J. et al. Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat. Commun. 8, 15290 (2017).","journal-title":"Nat. Commun."},{"issue":"3","key":"26858_CR22","first-page":"1102","volume":"12","author":"S Huang","year":"2022","unstructured":"Huang, S., Liu, Y., Chen, Z., Wang, M. & Jiang, V. C. PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma. Am. J. Cancer Res. 12 (3), 1102\u20131115 (2022).","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"26858_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/onc.2011.275","volume":"31","author":"T Smirnova","year":"2012","unstructured":"Smirnova, T. et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 31 (6), 706\u2013715 (2012).","journal-title":"Oncogene"},{"issue":"3","key":"26858_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3892\/ijo.2013.2229","volume":"44","author":"HQ Duong","year":"2014","unstructured":"Duong, H. Q. et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 44 (3), 959\u2013969 (2014).","journal-title":"Int. J. Oncol."},{"issue":"9","key":"26858_CR25","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1021\/acs.molpharmaceut.3c00216","volume":"20","author":"D Xiao","year":"2023","unstructured":"Xiao, D. et al. Preparation and evaluation of [(18)F]AlF-NOTA-PBB for PET imaging of Cyclin-dependent kinase 4\/6 in tumors. Mol. Pharm. 20 (9), 4528\u20134536 (2023).","journal-title":"Mol. Pharm."},{"issue":"3","key":"26858_CR26","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3892\/ol.2017.6526","volume":"14","author":"ZZ Shan","year":"2017","unstructured":"Shan, Z. Z., Chen, P. N., Wang, F., Wang, J. & Fan, Q. X. Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis. Oncol. Lett. 14 (3), 2859\u20132863 (2017).","journal-title":"Oncol. Lett."},{"issue":"4","key":"26858_CR27","first-page":"3734","volume":"18","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. Association between RNF2\u2009+\u2009P-AKT expression in pretreatment biopsy specimens, and poor survival following radiotherapy in patients with esophageal squamous cell carcinoma. Oncol. Lett. 18 (4), 3734\u20133742 (2019).","journal-title":"Oncol. Lett."},{"key":"26858_CR28","doi-asserted-by":"crossref","unstructured":"Yang, J. W. & Choi, Y. L. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine. Pathology Res. Practice 213(7), 836\u2013841 (2017).","DOI":"10.1016\/j.prp.2017.02.021"},{"issue":"2","key":"26858_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jss.2007.03.044","volume":"145","author":"R Mori","year":"2008","unstructured":"Mori, R. et al. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J. Surg. Res. 145 (2), 320\u2013326 (2008).","journal-title":"J. Surg. Res."},{"issue":"2","key":"26858_CR30","doi-asserted-by":"publisher","first-page":"e110833","DOI":"10.15252\/embj.2022110833","volume":"42","author":"B Sanz-Castillo","year":"2023","unstructured":"Sanz-Castillo, B. et al. The MASTL\/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner. EMBO J. 42 (2), e110833 (2023).","journal-title":"EMBO J."},{"issue":"3","key":"26858_CR31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/sj.leu.2402824","volume":"17","author":"F Chang","year":"2003","unstructured":"Chang, F. et al. Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (3), 590\u2013603 (2003).","journal-title":"Leukemia"},{"issue":"4","key":"26858_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/mco2.97","volume":"2","author":"L Saleh","year":"2021","unstructured":"Saleh, L., Wilson, C. & Holen, I. CDK4\/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. MedComm 2 (4), 514\u2013530 (2021).","journal-title":"MedComm"},{"issue":"7498","key":"26858_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature13176","volume":"509","author":"Y Song","year":"2014","unstructured":"Song, Y. et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509 (7498), 91\u201395 (2014).","journal-title":"Nature"},{"issue":"12","key":"26858_CR34","doi-asserted-by":"publisher","first-page":"e1864","DOI":"10.1634\/theoncologist.2020-0681","volume":"25","author":"TB Karasic","year":"2020","unstructured":"Karasic, T. B. et al. Phase II trial of Palbociclib in patients with advanced esophageal or gastric cancer. Oncologist 25 (12), e1864\u2013e1868 (2020).","journal-title":"Oncologist"},{"issue":"1","key":"26858_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41392-021-00682-5","volume":"6","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma. Signal. Transduct. Target. Therapy. 6 (1), 381 (2021).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"10","key":"26858_CR36","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41422-020-0333-6","volume":"30","author":"Y Cui","year":"2020","unstructured":"Cui, Y. et al. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 30 (10), 902\u2013913 (2020).","journal-title":"Cell Res."},{"issue":"1","key":"26858_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer cell. 41 (1), 181\u2013195e189 (2023).","journal-title":"Cancer cell."},{"issue":"1","key":"26858_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-017-1231-7","volume":"15","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. CDK4\/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J. Translational Med. 15 (1), 127 (2017).","journal-title":"J. Translational Med."},{"issue":"15","key":"26858_CR39","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/bph.13836","volume":"174","author":"L Chen","year":"2017","unstructured":"Chen, L. & Pan, J. Dual cyclin-dependent kinase 4\/6 Inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br. J. Pharmacol. 174 (15), 2427\u20132443 (2017).","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"26858_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-019-1112-1","volume":"19","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. The PI3K subunits, P110\u03b1 and P110\u03b2 are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol. Cancer. 19 (1), 10 (2020).","journal-title":"Mol. Cancer"},{"issue":"5","key":"26858_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/ng.2935","volume":"46","author":"DC Lin","year":"2014","unstructured":"Lin, D. C. et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat. Genet. 46 (5), 467\u2013473 (2014).","journal-title":"Nat. Genet."},{"issue":"5","key":"26858_CR42","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1053\/j.gastro.2016.01.035","volume":"150","author":"G Sawada","year":"2016","unstructured":"Sawada, G. et al. Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology 150 (5), 1171\u20131182 (2016).","journal-title":"Gastroenterology"},{"issue":"1","key":"26858_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12935-025-03686-1","volume":"25","author":"C Zhang","year":"2025","unstructured":"Zhang, C. et al. The genomic landscape of esophageal squamous cell carcinoma cell lines. Cancer Cell. Int. 25 (1), 174 (2025).","journal-title":"Cancer Cell. Int."},{"key":"26858_CR44","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.biopha.2018.07.075","volume":"106","author":"G Hou","year":"2018","unstructured":"Hou, G. et al. Down-regulation of rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt\/PRAS40 in esophageal squamous cell carcinoma. Biomed. pharmacotherapy = Biomedecine Pharmacotherapie. 106, 1348\u20131356 (2018).","journal-title":"Biomed. pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"26858_CR45","doi-asserted-by":"crossref","unstructured":"Badarni, M. et al. Repression of AXL expression by AP-1\/JNK blockage overcomes resistance to PI3Ka therapy. JCI Insight 5(8), (2019).","DOI":"10.1172\/jci.insight.125341"},{"issue":"1","key":"26858_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-023-01359-x","volume":"8","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Intact regulation of G1\/S transition renders esophageal squamous cell carcinoma sensitive to PI3K\u03b1 inhibitors. Signal. Transduct. Target. Therapy. 8 (1), 153 (2023).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"1","key":"26858_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41419-020-03370-4","volume":"12","author":"YX Wang","year":"2021","unstructured":"Wang, Y. X. et al. Adaptive resistance to PI3K\u03b1-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis. 12 (1), 85 (2021).","journal-title":"Cell Death Dis."},{"issue":"6","key":"26858_CR48","doi-asserted-by":"publisher","first-page":"987","DOI":"10.7150\/jca.22861","volume":"9","author":"N Wu","year":"2018","unstructured":"Wu, N. et al. The anti-tumor effects of dual PI3K\/mTOR inhibitor BEZ235 and histone deacetylase inhibitor trichostatin A on inducing autophagy in esophageal squamous cell carcinoma. J. Cancer. 9 (6), 987\u2013997 (2018).","journal-title":"J. Cancer"},{"issue":"1","key":"26858_CR49","doi-asserted-by":"publisher","first-page":"e53517","DOI":"10.1371\/journal.pone.0053517","volume":"8","author":"IM Ornelas","year":"2013","unstructured":"Ornelas, I. M., Silva, T. M., Fragel-Madeira, L. & Ventura, A. L. Inhibition of PI3K\/Akt pathway impairs G2\/M transition of cell cycle in late developing progenitors of the avian embryo retina. PloS One. 8 (1), e53517 (2013).","journal-title":"PloS One"},{"issue":"9","key":"26858_CR50","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/17425255.2019.1663169","volume":"15","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Molecular basis for class side effects associated with PI3K\/AKT\/mTOR pathway inhibitors. Expert Opin. Drug Metab. Toxicol. 15 (9), 767\u2013774 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"26858_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-018-0741-3","volume":"37","author":"D Cretella","year":"2018","unstructured":"Cretella, D. et al. The anti-tumor efficacy of CDK4\/6 Inhibition is enhanced by the combination with PI3K\/AKT\/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J. Exp. Clin. Cancer Res. 37 (1), 72 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"26858_CR52","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1158\/1078-0432.CCR-20-3624","volume":"27","author":"AS Clark","year":"2021","unstructured":"Clark, A. S., Makhlin, I. & DeMichele, A. Setting the pick: can PI3K inhibitors circumvent CDK4\/6 inhibitor resistance? Clin. Cancer Res. 27 (2), 371\u2013373 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"26858_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41420-025-02336-9","volume":"11","author":"C Chen","year":"2025","unstructured":"Chen, C. et al. TMEM45A enhances Palbociclib resistance and cellular Glycolysis by activating AKT\/mTOR signaling pathway in HR\u2009+\u2009breast cancer. Cell. Death Discov. 11 (1), 47 (2025).","journal-title":"Cell. Death Discov"},{"key":"26858_CR54","doi-asserted-by":"publisher","first-page":"216996","DOI":"10.1016\/j.canlet.2024.216996","volume":"597","author":"D Hu","year":"2024","unstructured":"Hu, D. et al. PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4\/6 inhibitor Palbociclib via PLK1 in B-cell lymphoma. Cancer Lett. 597, 216996 (2024).","journal-title":"Cancer Lett."},{"issue":"1","key":"26858_CR55","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1038\/s41467-025-58183-w","volume":"16","author":"H Xu","year":"2025","unstructured":"Xu, H. et al. Targeting CCNE1 amplified ovarian and endometrial cancers by combined Inhibition of PKMYT1 and ATR. Nat. Commun. 16 (1), 3112 (2025).","journal-title":"Nat. Commun."},{"issue":"1","key":"26858_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"26858_CR57","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Science: Publication Protein Soc. 28 (11), 1947\u20131951 (2019).","journal-title":"Protein Science: Publication Protein Soc."},{"issue":"D1","key":"26858_CR58","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51 (D1), D587\u2013d592 (2023).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26858-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26858-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26858-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:10:40Z","timestamp":1764331840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26858-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26858"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26858-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Animal Ethics Committee of the Affiliated Hospital of Nanjing University of Traditional Chinese Medicine for Integrative Medicine approved all the animal experiments (AEWC-20180727-43). All experiments were performed in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"42685"}}